Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)
- Registration Number
- NCT02262611
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to obtain long-term data on effects, safety and tolerability in routine medical practice and to investigate the potential of telmisartan to prevent secondary organ damage
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 266
Inclusion Criteria
- Adult patients of both gender aged >=18 admitted to a hospital due to insufficiently controlled essential hypertension.
No additional selection criteria have to be considered. Treatment was at the discretion of the physician following the summary of product information for Micardis® and MicardisPlus®
Read More
Exclusion Criteria
- not applicable
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hypertension patients - Nephrology Micardis® - Hypertension patients - Nephrology MicardisPlus® - Hypertension patients - Pneumology Micardis® - Hypertension patients - Pneumology MicardisPlus® - Hypertension patients - Cardiology Micardis® - Hypertension patients - Diabetology Micardis® - Hypertension patients - Cardiology MicardisPlus® - Hypertension patients - Diabetology MicardisPlus® -
- Primary Outcome Measures
Name Time Method Change in systolic blood pressure up to 1 year Number of patients with adverse events up to 1 year Number of patients with abnormal changes in laboratory parameters up to 1 year Change in diastolic blood pressure up to 1 year Number of patients with clinically significant changes in vital signs up to 1 year
- Secondary Outcome Measures
Name Time Method Global assessment of efficacy by investigator on a 4-point scale 2 weeks, after 1 year Global assessment of tolerability by investigator on a 4-point scale 2 weeks, after 1 year